Evidence map›Paper›PMID 40342876›Full record

ArticleHemaSphere2025

Peripheral T- and natural killer-cell lymphomas: ESMO-EHA Clinical Practice Guideline for diagnosis, treatment, and follow-up.

Francesco d'Amore, Massimo Federico, Laurence de Leval, Fredrik Ellin, Olivier Hermine, Won Seog Kim, François Lemonnier, Joost S P Vermaat, Gerald Wulf, Christian Buske and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HemaSphere, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Francesco d'AmoreDepartment of Haematology Aarhus University Hospital Aarhus Denmark.
Massimo FedericoCHIMOMO Department University of Modena and Reggio Emilia Emilia-Romagna Italy.
Laurence de LevalDepartment of Laboratory Medicine and Pathology Institute of Pathology, Lausanne University Hospital Lausanne University Lausanne Switzerland.
Fredrik EllinDepartment of Clinical Sciences Lund University Lund Sweden.
Olivier HermineDepartment of Hematology Université de Paris, Assistance Publique-Hôpitaux de Paris (AP-HP) Paris France.
Won Seog KimSchool of Medicine, Samsung Medical Center Sungkyunkwan University Seoul Korea.
François LemonnierLymphoid Malignancies Unit Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP) Créteil France.
Joost S P VermaatDepartment of Hematology Leiden University Medical Centre Leiden The Netherlands.
Gerald WulfDepartment of Hematology and Medical Oncology University Medical Center Göttingen Göttingen Germany.
Christian BuskeInstitute of Experimental Cancer Research Ulm Medical University Ulm Sweden.
Martin DreylingDepartment of Medicine III Ludwig Maximilian University Munich Germany.
Mats JerkemanDepartment of Oncology Skåne University Hospital Lund Sweden.
ESMO and EHA Guidelines Committees

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40342876
PMCPMC12059256

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.